FREE Account Opening + No Clearing Fees

Deccan Healthcare BSE SME IPO Dec. 2018 review (May apply)

Review By Dilip Davda on December 14, 2018

•    DHL is emerging online Nutraceutical food supplement product supplier.
•    Company is doing aggressive marketing with its 'Beyoungbharat' initiatives.
•    Imported plant and machinery to boost export earnings.
•    Added investors like Kent RO, Valuewise, DS Group etc in recent past.

Deccan Health Care Ltd. (DHL) that announced its maiden IPO in December last postponed the same due to procedural lapses on disclosures. It has now cleaned the slat and is mulling afresh IPO with modified terms. The company is into developing, manufacturing and marketing a broad range of healthcare products including nutraceutical, cosmeceutical and Ayurveda products and is known for the premium range of products in all these categories.

While it is marketing its products online as well as offline, it gives major thrust for online marketing that gave them the desired level of operations with over 1.65 lakh online loyal customers. The company follows the concept of 'Prevention is better than cure' and is competing with multinational brands that are sold at higher premiums. DHL's online portals for e-commerce are and The company uses natural ingredients for its product formulas. It is installing new imported plant and machineries to boost its export earnings. USP for DHL is its dealing in FMCH (Fast Moving Consumer Healthcare) products that is fast growing sector.

The company has the ability to supply products in various forms such as tablets, capsules, gel, liquids, ointments, powder, pastes etc. It is an ISO 9001:2008 certified and FSSAI license company. It has PAN India presence with over 140 distributors and 6100 marketing agents. It has also entered into 2 distributorship agreements with foreign distributors situated in Kenya and Tanzania. DHL's products are marketed under brand names like 'Stay Wow', 'Be Young', 'My Nutridecc', 'Pharma Decc' and 'Stay Young'.  It has identified over 50 consumer wellness goals and over 200 diseases, disorders, disabilities which can be prevented by meeting RDA of micronutrients and it has innovated and developed cost-effective products that are unique and differentiated to combat such diseases.

The company is participating in recently announced 'Ayushman Bharat' with its 'beyoungbharat' initiatives that will help it to boost its play in nutraceutical supplement doses.

To part finance repayment/prepayment of certain debts, purchase of plant and machinery and related civil work, working capital and general corpus fund needs, DHL is coming out with a maiden IPO of 4212000 equity shares of Rs. 10 each by way of book building route with a price band of Rs. 95-100 per share to mobilize Rs. 40.01 cr. to -42.12 cr.  cr. (based on lower and upper price bands). The issue comprises of fresh equity issue of 2212000 shares and offer for sale (OFS) of 2000000 shares. The issue opens for subscription on 18.12.18 and will close on 20.12.18. Minimum application is to be made for 1200 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on BSE SME. Issue constitutes 26.81% of the post issue paid up capital of the company. The issue is solely lead managed by Pantomath Capital Advisor Pvt. Ltd. while Bigshare Services Pvt. Ltd. is the registrar to the issue.

Having issued initial and subsequent equity at par, it also raised further equity in the price range of Rs. 16.80 to Rs. 35 per share between February 2008 and February 2018. It has also issued bonus shares in the ratio of 1 for 1 in January 2002. The average cost of acquisition of shares by the promoters is 'Not Determinable' and Rs. 0.11 per share. Post issue, its current paid up equity capital of Rs. 13.50 cr. will stand enhanced to Rs.15.71 cr.



On the performance front, for the last four fiscals, DHL has posted turnover/net profits of Rs. 16.18 cr. / Rs. 3.54 cr. (FY16) and Rs. 29.39 cr. / Rs. 9.54 cr. (FY17) and Rs. 39.76 cr. / Rs. 12.69 cr. (FY18). For the Q1 of FY19, it has earned a net profit of Rs. 2.46 cr. on a turnover of Rs. 8.59 cr. For the last three fiscals, it has posted an average EPS of Rs. 8.81 and an average RoNW of 38.77%.

The issue is priced at a P/BV of 3.47 on the basis of its NAV of Rs.28.84 as on 30.06.18. On the basis of its earnings for FY18 issue is priced at a P/E of 12.4. If we annualize latest earnings and attribute it on fully diluted equity post issue, then asking price is at a P/E of 16. According to management company has historical trends of higher turnover and profits from rainy season i.e. Q2 onwards and are confident of maintaining such trends going forward.

As per offer document, it has shown Zydus Wellness as its listed peer that is currently trading at a P/E of around 37.8 (as on 14.12.18 closing).

On merchant banker's front, this is the 75th mandate from its stable in last three fiscals. Out of last 10 listings, all opened with a premium ranging from 0.05% to 8% on the day of listing.

Conclusion / Investment Strategy

DHL's original IPO launch plan in March/April 2018 was called off soon after announcement due to some technical lapses and is now finally on. The Company has proven track record of improved financials year after year. It has a creamy list of investors (that includes Kent RO, Valueworth Capital, DS Group etc.) in pre-IPO placements. Post issue, company will turn debt free and will have better earnings. Considering all these, Investors may considered it for long term.

Review By Dilip Davda on December 14, 2018

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: ).

Deccan Health Care IPO FAQs

  1. 1. Why Deccan Health Care IPO?

    The initial public offer (IPO) of Deccan Health Care Limited offers an early investment opportunity in Deccan Health Care Limited. A stock market investor can buy Deccan Health Care IPO shares by applying in IPO before Deccan Health Care Limited shares get listed at the stock exchanges. An investor could invest in Deccan Health Care IPO for short term listing gain or a long term.

  2. 2. How is Deccan Health Care IPO?

    Read the Deccan Health Care IPO recommendations by the leading analyst and leading stock brokers.

  3. 3. Deccan Health Care IPO what should investors do?

    Deccan Health Care IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the Deccan Health Care IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  4. 4. Is Deccan Health Care IPO good?

    Our recommendation for Deccan Health Care IPO is to subscribe for long term.

  5. 5. Is Deccan Health Care IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to subscribe for long term to the Deccan Health Care IPO.

  6. 6. When will Deccan Health Care IPO allotment status?

    The Deccan Health Care IPO allotment status will be available on or around December 26, 2018. The allotted shares will be credited in demat account by December 28, 2018. Visit Deccan Health Care IPO allotment status to check.

  7. 7. When will Deccan Health Care IPO list?

    The Deccan Health Care IPO will list on Monday, December 31, 2018, at BSE SME.